Fintel reports that on September 22, 2025, BMO Capital upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Market Perform to Outperform.
Analyst Price Forecast Suggests 93.33% Upside
As of September 13, 2025, the average one-year price target for Sarepta Therapeutics is $33.70/share. The forecasts range from a low of $5.05 to a high of $194.25. The average price target represents an increase of 93.33% from its latest reported closing price of $17.43 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sarepta Therapeutics is 2,694MM, an increase of 8.56%. The projected annual non-GAAP EPS is 1.49.
What is the Fund Sentiment?
There are 874 funds or institutions reporting positions in Sarepta Therapeutics. This is an decrease of 60 owner(s) or 6.42% in the last quarter. Average portfolio weight of all funds dedicated to SRPT is 0.11%, an increase of 42.65%. Total shares owned by institutions increased in the last three months by 0.09% to 111,965K shares. 
The put/call ratio of SRPT is 0.69, indicating a bullish outlook.
What are Other Shareholders Doing?
D. E. Shaw holds 4,479K shares representing 4.58% ownership of the company. In its prior filing, the firm reported owning 4K shares , representing an increase of 99.90%. The firm increased its portfolio allocation in SRPT by 21,591.97% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 3,201K shares representing 3.28% ownership of the company. In its prior filing, the firm reported owning 3,115K shares , representing an increase of 2.70%. The firm decreased its portfolio allocation in SRPT by 74.04% over the last quarter.
AGTHX - GROWTH FUND OF AMERICA holds 3,152K shares representing 3.23% ownership of the company. In its prior filing, the firm reported owning 3,155K shares , representing a decrease of 0.09%. The firm decreased its portfolio allocation in SRPT by 17.90% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,025K shares representing 3.10% ownership of the company. In its prior filing, the firm reported owning 2,866K shares , representing an increase of 5.28%. The firm decreased its portfolio allocation in SRPT by 74.76% over the last quarter.
AMCPX - AMCAP FUND holds 2,666K shares representing 2.73% ownership of the company. In its prior filing, the firm reported owning 2,525K shares , representing an increase of 5.30%. The firm decreased its portfolio allocation in SRPT by 12.58% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
